公开(公告)号：US20200268882A1

公开(公告)日：2020-08-27

申请号：US16872473

申请日：2020-05-12

申请人： Richard Louis Price

发明人： Richard Louis Price

IPC分类号： A61K39/395 ,  A23L3/3553 ,  C07F9/117 ,  A61K31/4168 ,  A61K31/155 ,  A61K31/165 ,  A61K9/00 ,  A61K31/047 ,  A61K45/06 ,  A61J1/00

摘要： Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

公开(公告)号：US10688179B2

公开(公告)日：2020-06-23

申请号：US16529400

申请日：2019-08-01

申请人： Richard Louis Price

发明人： Richard Louis Price

IPC分类号： A61K39/395 ,  A23L3/3553 ,  C07F9/117 ,  A61K31/4168 ,  A61K31/155 ,  A61K31/165 ,  A61K9/00 ,  A61K31/047 ,  A61K45/06 ,  A61J1/00 ,  A61K39/00

摘要： Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

公开(公告)号：US20190177347A1

公开(公告)日：2019-06-13

申请号：US16327735

申请日：2017-08-30

申请人： The Board of Trustees of The Leland Stanford Junior University

发明人： Noah Burns ,  Steven R. Shuken ,  Jaron A.M. Mercer ,  Carolyn M. Cohen

IPC分类号： C07F9/117 ,  A61K9/127 ,  C07C1/32 ,  C07C2/42 ,  C07F5/02 ,  C07C29/17 ,  C07C45/69 ,  C07C13/62 ,  C07C49/693 ,  C07C53/136 ,  C07C31/137

CPC分类号： C07F9/117 ,  A61K9/1271 ,  C07C1/30 ,  C07C1/322 ,  C07C2/42 ,  C07C13/62 ,  C07C29/09 ,  C07C29/095 ,  C07C29/172 ,  C07C31/137 ,  C07C41/18 ,  C07C41/20 ,  C07C45/68 ,  C07C45/69 ,  C07C49/693 ,  C07C51/16 ,  C07C53/136 ,  C07C69/608 ,  C07C2602/18 ,  C07C2603/40 ,  C07C2603/52 ,  C07F5/025 ,  C07C13/38 ,  C07C33/05 ,  C07C49/753 ,  C07C43/21

摘要： Methods for preparing a variety of ladderane precursors, ladderane compounds and ladderane lipids are provided. Also provided are methods of preparing a liposome from the ladderane lipids disclosed herein, and compositions thereof. Aspects of the invention include encapsulated one or more cargo moieties in the liposome or compositions thereof and use of the subject liposome compositions as vehicles in drug delivery, imaging, diagnostics and other medical applications. Aspects of the methods disclosed herein include administering a liposomal composition comprising a pharmaceutical agent to a subject under conditions sufficient to deliver the composition to a site of interest in the subject, and release the pharmaceutical agent from the liposomal composition.

公开(公告)号：US10106562B2

公开(公告)日：2018-10-23

申请号：US14774944

申请日：2014-03-13

申请人： Lantheus Medical Imaging, Inc.

发明人： Tarakeshwar Anklekar ,  Jan Haller ,  Nicolas Champion ,  Franz-Willi Herkenrath

IPC分类号： C07F9/117 ,  C07F9/6506 ,  C07F9/146 ,  A61K49/10 ,  A61K31/685 ,  A61K49/04

摘要： This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.

公开(公告)号：US20170349516A1

公开(公告)日：2017-12-07

申请号：US15487623

申请日：2017-04-14

申请人： Esperion Therapeutics, Inc.

发明人： Jean-Louis H. Dasseux ,  Carmen D. Oniciu

IPC分类号： C07C31/27 ,  C07F9/24 ,  A61K31/191 ,  A61K31/194 ,  C07F9/12 ,  C07F9/117 ,  C07F9/11 ,  C07F9/09 ,  C07D495/04 ,  C07D405/12 ,  C07D309/30 ,  C07D309/12 ,  C07D309/10 ,  C07D307/33 ,  C07D305/12 ,  C07D261/12 ,  C07D261/08 ,  C07D257/04 ,  C07D213/80 ,  C07C309/25 ,  C07C309/24 ,  C07C309/08 ,  C07C255/00 ,  C07C69/757 ,  C07C69/675 ,  C07C69/017 ,  C07C69/003 ,  C07C65/17 ,  C07C62/06 ,  C07C62/02 ,  C07C61/12 ,  C07C59/54 ,  C07C59/48 ,  C07C59/46 ,  C07C59/29 ,  C07C59/285 ,  C07C59/245 ,  C07C59/11 ,  C07C59/105 ,  C07C59/01 ,  C07C47/34 ,  C07C47/19 ,  C07C33/26 ,  C07C31/24 ,  C07C31/22 ,  C07C31/20 ,  A61K31/23 ,  A61K31/20 ,  C07F9/44 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08

CPC分类号： C07C31/27 ,  A61K31/191 ,  A61K31/194 ,  A61K31/20 ,  A61K31/23 ,  C07C31/20 ,  C07C31/22 ,  C07C31/24 ,  C07C33/26 ,  C07C47/19 ,  C07C47/34 ,  C07C59/01 ,  C07C59/105 ,  C07C59/11 ,  C07C59/245 ,  C07C59/285 ,  C07C59/29 ,  C07C59/46 ,  C07C59/48 ,  C07C59/54 ,  C07C61/12 ,  C07C62/02 ,  C07C62/06 ,  C07C65/17 ,  C07C69/003 ,  C07C69/017 ,  C07C69/675 ,  C07C69/757 ,  C07C255/00 ,  C07C309/08 ,  C07C309/24 ,  C07C309/25 ,  C07C2101/02 ,  C07C2101/04 ,  C07C2101/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07D213/80 ,  C07D257/04 ,  C07D261/08 ,  C07D261/12 ,  C07D305/12 ,  C07D307/33 ,  C07D309/10 ,  C07D309/12 ,  C07D309/30 ,  C07D405/12 ,  C07D495/04 ,  C07F9/093 ,  C07F9/094 ,  C07F9/11 ,  C07F9/117 ,  C07F9/12 ,  C07F9/2408 ,  C07F9/2416 ,  C07F9/242 ,  C07F9/2425 ,  C07F9/4423

摘要： The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

公开(公告)号：US20170298083A1

公开(公告)日：2017-10-19

申请号：US15513002

申请日：2015-09-28

申请人： Bernhard-Nocht-Institut für Tropenmedizin ,  Forschungszentrum Borstel

发明人： Hannelore Lotter ,  Hannah Bernin ,  Egbert Tannich ,  Nestor Gonzalez-Roldan ,  Yukari Fujimoto ,  Koichi Fukase

IPC分类号： C07F9/117 ,  C07H15/207 ,  A61K39/00

CPC分类号： C07F9/117 ,  A61K31/683 ,  A61K31/7034 ,  A61K35/15 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/55511 ,  C07F9/6552 ,  C07F9/65586 ,  C07H15/207 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/478 ,  Y02A50/486 ,  Y02A50/487

摘要： The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan Entamoeba histolytica. The compounds have been found to be useful for enhancing and/or inducing an immune response in a subject in need thereof. Specifically, the compounds have been found to be useful for the treatment of cancer diseases, such as breast cancer, and parasitic diseases, such as leishmaniasis. The invention also provides pharmaceutical compositions comprising the novel compounds.

公开(公告)号：US09732029B2

公开(公告)日：2017-08-15

申请号：US14444750

申请日：2014-07-28

申请人： Cardioxyl Pharmaceuticals, Inc.

发明人： Lisa Marie Frost ,  Stephen Martin Courtney ,  Frederick Arthur Brookfield ,  Vincent Jacob Kalish

IPC分类号： C07C207/04 ,  C07C207/00 ,  C07D309/14 ,  C07D407/12 ,  C07D211/44 ,  C07D211/58 ,  C07D333/42 ,  C07D405/12 ,  C07D405/14 ,  C07D451/10 ,  C07F9/117 ,  C07F9/58 ,  C07C255/19 ,  C07D309/10 ,  C07F9/59

CPC分类号： C07C207/00 ,  C07C207/04 ,  C07C255/19 ,  C07D211/44 ,  C07D211/58 ,  C07D309/10 ,  C07D309/14 ,  C07D333/42 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D451/10 ,  C07F9/117 ,  C07F9/58 ,  C07F9/59

摘要： The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

公开(公告)号：US09725402B2

公开(公告)日：2017-08-08

申请号：US14927994

申请日：2015-10-30

申请人： Cardioxyl Pharmaceuticals, Inc.

发明人： Lisa Marie Frost ,  Stephen Martin Courtney ,  Frederick Arthur Brookfield ,  Vincent Jacob Kalish

IPC分类号： C07C207/04 ,  C07C207/00 ,  C07D309/14 ,  C07D407/12 ,  C07D211/44 ,  C07D211/58 ,  C07D333/42 ,  C07D405/12 ,  C07D405/14 ,  C07D451/10 ,  C07F9/117 ,  C07F9/58 ,  C07C255/19 ,  C07D309/10 ,  C07F9/59

CPC分类号： C07C207/00 ,  C07C207/04 ,  C07C255/19 ,  C07D211/44 ,  C07D211/58 ,  C07D309/10 ,  C07D309/14 ,  C07D333/42 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D451/10 ,  C07F9/117 ,  C07F9/58 ,  C07F9/59

摘要： The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

公开(公告)号：US20160016979A1

公开(公告)日：2016-01-21

申请号：US14774944

申请日：2014-03-13

申请人： LANTHEUS MEDICAL IMAGING, INC.

发明人： Tarakeshwar Anklekar ,  Jan Haller ,  Nicolas Champion ,  Franz-Willi Herkenrath

IPC分类号： C07F9/117 ,  A61K31/685 ,  A61K49/10 ,  A61K49/04 ,  C07F9/6506 ,  C07F9/146

CPC分类号： C07F9/117 ,  A61K31/685 ,  A61K49/04 ,  A61K49/106 ,  C07F9/146 ,  C07F9/6506

摘要： This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.

摘要翻译： 本申请涉及制备钆膦一水合三水合物的药学上可接受的制剂的方法，其中该方法使用不超过一个色谱纯化来除去杂质。

公开(公告)号：US09199908B2

公开(公告)日：2015-12-01

申请号：US14490014

申请日：2014-09-18

申请人： United Therapeutics Corporation

发明人： Ken Phares ,  David Mottola ,  Roger Jeffs ,  Michael Wade

IPC分类号： A01N37/00 ,  A01N37/10 ,  A61K31/215 ,  A61K31/21 ,  A61K31/19 ,  C07C69/96 ,  C07C327/00 ,  C07F9/02 ,  C07C59/13 ,  C07C59/70 ,  C07C69/712 ,  C07C229/08 ,  C07C235/06 ,  C07C235/08 ,  C07C259/06 ,  C07F9/09 ,  C07F9/117 ,  C07C51/41 ,  A61K31/235

CPC分类号： C07C59/13 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/192 ,  A61K31/216 ,  A61K31/223 ,  A61K31/235 ,  C07C51/412 ,  C07C59/70 ,  C07C69/712 ,  C07C229/08 ,  C07C235/06 ,  C07C235/08 ,  C07C259/06 ,  C07C2103/10 ,  C07C2603/10 ,  C07F9/091 ,  C07F9/117

摘要： This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

摘要翻译： 本发明一般涉及前列环素制剂及其用于促进血管舒张，抑制血小板聚集和血栓形成，刺激溶栓，抑制细胞增殖（包括血管重构），提供细胞保护，预防动脉粥样硬化和诱导血管生成的方法。